Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Cresset Asset Management LLC

Cresset Asset Management LLC boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 11.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,765 shares of the company's stock after purchasing an additional 7,557 shares during the quarter. Cresset Asset Management LLC owned about 0.13% of Harmony Biosciences worth $2,469,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. BOKF NA raised its position in Harmony Biosciences by 4.7% during the 4th quarter. BOKF NA now owns 15,400 shares of the company's stock worth $521,000 after buying an additional 690 shares during the last quarter. Brevan Howard Capital Management LP purchased a new position in Harmony Biosciences during the 4th quarter worth $1,491,000. BNP Paribas Financial Markets purchased a new position in Harmony Biosciences during the 4th quarter worth $2,025,000. Ameriprise Financial Inc. grew its holdings in Harmony Biosciences by 22.0% during the fourth quarter. Ameriprise Financial Inc. now owns 103,801 shares of the company's stock worth $3,572,000 after acquiring an additional 18,730 shares during the period. Finally, Algert Global LLC grew its holdings in Harmony Biosciences by 153.9% during the fourth quarter. Algert Global LLC now owns 230,908 shares of the company's stock worth $7,946,000 after acquiring an additional 139,967 shares during the period. Hedge funds and other institutional investors own 86.23% of the company's stock.

Harmony Biosciences Trading Up 2.1%

Harmony Biosciences stock traded up $0.71 during trading on Thursday, reaching $34.10. The company had a trading volume of 165,283 shares, compared to its average volume of 590,769. Harmony Biosciences Holdings, Inc. has a 12-month low of $26.47 and a 12-month high of $41.61. The stock's 50 day moving average price is $31.43 and its two-hundred day moving average price is $34.02. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 16.18, a PEG ratio of 0.47 and a beta of 0.82. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. During the same period in the previous year, the firm earned $0.67 earnings per share. Harmony Biosciences's revenue for the quarter was up 19.5% on a year-over-year basis. As a group, equities analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on HRMY shares. UBS Group dropped their price objective on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Monday, April 28th. Needham & Company LLC reiterated a "buy" rating and issued a $49.00 price target on shares of Harmony Biosciences in a report on Tuesday, May 6th. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a "strong-buy" rating in a report on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. Finally, Mizuho raised their target price on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a report on Thursday. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $52.78.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.